DNA Technology
DNA Technology refers to the science and commercial application of analyzing, sequencing, synthesizing, editing, and manipulating genetic material to improve healthcare, biotechnology, agriculture, forensics, and industrial research. The sector includes genomics platforms, genetic testing, CRISPR-based innovation, molecular diagnostics, synthetic biology, and bioinformatics solutions driving precision medicine and next-generation biological advancement.

Rapid DNA as a Catalyst for Accelerated Discovery
Rapid DNA technology represents a monumental leap in molecular biology, shifting the paradigm from a lengthy, lab-centric process to an immediate, on-site capability. By automating and miniaturizing the complex workflows of DNA extraction, amplification, separation, and detection into a single, portable instrument, it has become a powerful catalyst for accelerated discovery. This innovation is not merely an incremental improvement in speed; it is a transformative force that collapses the time and distance between a biological sample and actionable genetic insight. The ability to generate a complete DNA profile in under two hours, directly at the point of need, is unlocking new frontiers in fields ranging from criminal justice to global health and environmental science.
What Executives Should Demand From DNA Technology
DNA technology has moved from a specialist laboratory function into a decision tool for public safety, health surveillance, border security, disaster response and biological threat monitoring. That shift raises the bar for buyers. A platform can no longer be judged only by scientific promise or laboratory accuracy under ideal conditions. It must demonstrate the ability to deliver reliable, useful information rapidly enough to enable timely decisions and maintain evidentiary integrity, data security and usability outside the laboratory.

Leslie Hurst serves as associate vice president of specialty pharmacy & PBM strategy at Baptist Health System (KY & IN). With extensive experience leading specialty pharmacy programs, she directs formulary strategy, benefit optimization and team operations, driving improved access, affordability and clinical outcomes across the health system. With a Doctor of Pharmacy from the University of Kentucky and board certification in ambulatory care, she excels in strategic planning and operational excellence. A former Walgreens specialty supervisor, she has advanced clinical practice, built high-performing teams, and enhanced medication adherence and outcomes. Hurst also champions health equity through speaking engagements (e.g., NASP) and community outreach, reinforcing her commitment to innovative, patient-centered care.
